399 THORNALL STREET, EDISON, NJ
Hepion Pharmaceuticals Enters $500,000 Convertible Note Agreement with Gravitas
Hepion Pharmaceuticals Enters $400,000 Securities Purchase Agreements
Director Appointment - James Liddy Joins Hepion Pharmaceuticals Board
Board Appointment - Danina Fisher and Gary S. Stetz, II Join Directors
Hepion Pharmaceuticals 2026 Annual Meeting Results; Directors Elected
Annual Report to Security Holders
Hepion Pharmaceuticals Enters $700,000 Securities Purchase Agreement
Material disclosure
Q2
Q1
Q3
Notice of Late Filing for Quarterly Report
FY 2024
Notice of Late Filing for Annual Report
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Prospectus Filed Pursuant to Rule 425
Definitive Proxy Statement
PRER14A
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
S-1MEF